Hongtao Lu
Co-Founder Elpiscience Biopharma
Seminars
Thursday 11th June 2026
A First-in-Class CD39-TGFb-trap Bispecific Antibody With Strong Single Agent Clinical Activity in Solid Tumors
4:00 pm
- Outlining the biological rationale and design of the molecule
- Discussing MoA and preclinical data
- Sharing Phase I clinical efficacy and safety data, as well as detailed clinical data in desmoid tumor
